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Effect of donor type and conditioning regimen intensity on 
allogeneic transplantation outcomes in patients with sickle 
cell disease: a retrospective multicentre, cohort study
Mary Eapen, Ruta Brazauskas, Mark C Walters, Françoise Bernaudin, Khalid Bo-Subait, Courtney D Fitzhugh, Jane S Hankins, Julie Kanter, 
Joerg J Meerpohl, Javier Bolaños-Meade, Julie A Panepinto, Damiano Rondelli, Shalini Shenoy, Joi Williamson, Teonna L Woolford, Eliane Gluckman, 
John E Wagner*, John F Tisdale*
Summary
Background Donors other than matched siblings and low-intensity conditioning regimens are increasingly used in 
haematopoietic stem cell transplantation. We aimed to compare the relative risk of donor type and conditioning 
regimen intensity on the transplantation outcomes of in patients with sickle cell disease.
Methods For this retrospective cohort study, we collected data from 90 US centres reported to the Center for 
International Blood and Marrow Transplant Research. Eligible patients were younger than 50 years, had genetically 
confirmed sickle cell disease (Hb SS) or sickle beta thalassemia (Hb Sβ), and underwent allogeneic haematopoietic 
cell transplantation between Jan 15, 2008, and Dec 28, 2017. We considered transplants from donor-recipient pairs 
matched at the allele-level (HLA-A, HLA-B, HLA-C, and HLA-DRB1), including HLA-matched sibling donors, 
haploidentical related donors, matched unrelated donors, or mismatched unrelated donors. The main outcome was 
event-free survival. The effect of donor type, conditioning regimen intensity (myeloablative, non-myeloablative, and 
reduced-intensity regimens), age (≤12 or 13-49 years), sex, performance score, comorbidity index, recipient 
cytomegalovirus serostatus, graft type (bone marrow, peripheral blood, or umbilical cord blood), and transplantation 
period (2008–12 and 2013–17) on outcomes was studied using Cox regression models.
Findings Of 996 patients with sickle cell disease and who underwent transplantation in 2008–17, 910 (91%) were included 
(558 [61%] patients had HLA-matched sibling donors, 137 [15%] haploidentical related donors, 111 [12%] matched unrelated 
donors, and 104 [11%] mismatched unrelated donors). The median follow-up was 36 months (IQR 18–60) after 
transplantation from HLA-matched siblings, 25 months (12–48) after transplantation from haploidentical related donors, 
37 months (23–60) after transplantation from HLA-matched unrelated donors, and 47 months (24–72) after transplantation 
from mismatched unrelated donors. Event-free survival was worse in recipients aged 13 years or older than in those 
younger than 13 years (hazard ratio 1·74, 95% CI 1·24–2·45; p=0·0014) and in those who received a transplant from 
haploidentical related donors (5·30, 3·17–8·86; p<0·0001), matched unrelated donors (3·71, 2·39–5·75; p<0·0001), and 
mismatched unrelated donors (4·34, 2·58–7·32; p<0·0001) than in patients who received a transplant from matched 
siblings. There was no significant difference in event-free survival between recipients of transplants from non-sibling 
donors: haploidentical related donors (1·43, 0·81–2·50; p=0·21) or mismatched unrelated donors (1·17, 0·67–2·05; 
p=0·58) versus HLA-matched unrelated donors, or mismatched unrelated donors versus haploidentical related donors 
(1·22, 0·65–2·27; p=0·98). Event-free survival was also worse in patients conditioned with reduced-intensity regimens 
(1·97, 1·15–3·36; p=0·013) than in those conditioned with non-myeloablative regimens, but did not differ between those 
who received myeloablative compared with non-myeloablative regimens (1·57, 0·95–2·61; p=0·079). Interpretation Our 
data suggest that event-free survival is improved in patients with sickle cell disease who receive an allogenic transplantation 
at age 12 years or younger and those with an HLA-matched sibling donor. For patients without a matched sibling available 
for transplantation, our data do not favour one alternative donor type over another in this setting. 
Funding National Institutes of Health and US Health Services Research Administration, Department of Health and 
Human Services.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
Sickle cell disease is the most common inherited 
haemoglobinopathy and occurs in one in 500 African-
American and one in 1000–1400 Hispanic-American 
births. Worldwide, over 270 000 affected infants are born 
annually. For children with access to modern health care, 
overall survival at 18 years of age is 85·6% (73·4–97·8).1 
The life expectancy of adults with sickle cell disease is 
shortened by at least two decades compared to the 
general population.2,3 Risk factors associated with 
mortality in adults include age, gender, elevated tricuspid 
valve regurgitation velocity, intensity of haemolytic 
anaemia, and elevated blood concentrations of ferritin, 
creatinine, and aspartate transaminase.3,4 Haematopoietic 
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cell transplantation is potentially curative for sickle cell 
disease but the treatment itself is associated with 
substantial risks which can limit its use. Although the 
probability of overall survival is approximately 90% at 
5 years after transplantation in recipients of a human 
leukocyte antigen (HLA)-matched sibling transplant,5–8 
access is limited by donor availability. As a result, 
alternative donor sources have been explored. Because of 
the rarity of HLA haplotypes observed in patients 
of African-descent, matched unrelated donors are 
infrequent,9 therefore grafts from haploidentical related 
or mismatched unrelated donors often have to be 
used.10–13 Treatment failure is primarily attributed to graft 
failure after transplantations from mismatched related 
donors10 and to development of chronic graft-versus-host 
disease (GVHD) after transplantation from matched 
unrelated donors.11
Data reported to the Center for International Blood and 
Marrow Transplant Research (CIBMTR) indicate 
increasing numbers of transplantations from alternative 
donors, in particular for young adults, and the use of 
conditioning regimens that are not full intensity (ie, 
myeloablation) in the USA. Therefore, this study sought 
to compare the relative risks of donor type and 
conditioning regimen intensity on outcomes after 
allogeneic transplantation for sickle cell disease in 
2008–17, a period during which alternative donors and 
reduced intensity and non-myeloablative conditioning 
regimens were increasingly used for transplantation.
Methods
Study design and participants
The CIBMTR is a working group of more than 
300 transplant centres worldwide that contribute data on 
consecutive allogeneic and autologous transplantations 
for different indications. Patients are followed lon-
gitudinally until death or lost to follow-up. Accuracy of 
data reported to the CIBMTR and compliance are 
monitored by on-site audits. Consent for research is 
sought from patients or their legal guardians. The 
Institutional Review Board of the National Marrow 
Donor Program approved this study.
We retrospectively reviewed data from 90 US centres 
reported to the CIBMTR. We included patients younger 
than 50 years (7 patients aged 50 years or older were 
excluded, this group are more likely to have transplant-
related complications including death), who had 
genetically confirmed sickle cell disease (Hb SS) or sickle 
beta thalassemia (Hb Sβ), and underwent allogeneic 
haematopoietic cell transplantation between Jan 15, 2008, 
and Dec 28, 2017, including transplants from HLA-
matched sibling donors, haploidentical related donors, 
matched unrelated donors, or mismatched unrelated 
donors.
We excluded patients from two transplant centres that 
failed data accuracy audit, including patients who received 
conditioning regimens rarely used for sickle cell disease 
(ie, off-label regimens containing treosulfan and total body 
irradiation [TBI] ≥1000 cGy), patients who did not receive 
prophylaxis for GVHD, and patients who were inadequately 
followed up after transplantation.
Procedures
We retrieved the following information for all eligible 
patients from the CIBMTR: donor type (patients were 
grouped by donor type, including HLA-matched sibling, 
haploidentical related donors, and HLA-matched and 
mismatched unrelated donors, and donor-recipient pairs 
Research in context
Evidence before the study
We searched MEDLINE from Jan 1, 2011, to Aug 29, 2018, for 
articles on sickle cell disease published after 2010, with the search 
terms “sickle cell disease”, “HLA-matched sibling”, 
“haploidentical”, “unrelated”, and “transplant”. In addition to 
two reports of transplantations from HLA-matched sibling 
donors, we identified five reports of transplantations from 
haploidentical and unrelated donors but they were limited to 
small numbers of patients. We did not identify any reports that 
compared outcomes after transplantations from HLA-matched 
siblings, haploidentical donors, or unrelated donors in patients 
with sickle cell disease. Furthermore, the heterogeneity of 
transplant conditioning regimens in the reports made it 
impossible to assess the effect of conditioning regimen intensity 
on transplantation outcomes for patients with sickle cell disease.
Added value of the study
To our knowledge this is the first study to compare transplant 
outcomes by donor type for sickle cell disease. In a population 
of 910 patients we recorded improved event-free survival 
and overall survival for patients who received transplantation 
from HLA-matched siblings compared to other allogeneic 
transplantation types. The occurrence of graft failure was 
increased after transplantation from alternative donors 
compared with transplantations from HLA-matched sibling. 
Implications of all the available evidence
There are publications with fewer than 30 patients that have 
reported outcomes using alternative donors but not a direct 
comparison as we have undertaken. A direct comparison of 
available donor types has offered an unique opportunity to 
address barriers to success after alternative donor 
transplantation. Well designed phase 2 trials that investigate 
strategies to overcome graft failure after transplantation from 
alternative donor and increased prevalence of graft-versus-host 
disease after transplantation from unrelated donors are needed. 
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were HLA-matched at the allele-level [HLA-A, HLA-B, 
HLA-C, and HLA-DRB1]), conditioning regimen intensity 
(myeloablative, non-myeloablative, and reduced-intensity 
regimens), age, sex, performance score (Lansky play 
scale or Karnofsky performance score), comorbidity 
index (hematopoietic cell transplant comorbidity index 
score), recipient cytomegalovirus serostatus, graft type 
(bone marrow, peripheral blood, or umbilical cord blood), 
and transplantation period (2008–12 and 2013–2017).
Conditioning regimen for patients was either myelo-
ablative, reduced intensity, or non-myeloablative, and was 
established on the basis of previously defined criteria.14 
Briefly, regimens were considered myeloablative when 
busulfan was administered orally at a concentration 
greater than 8 mg/kg or intravenously at a concentration 
greater than 6 mg/kg, or melphalan was administered at 
concen trations greater than 150 mg/m². Regimens using 
lower doses of busulfan or melphalan (administered 
without another alkylating agent) were considered 
reduced intensity. TBI regimens (dose 200–400 cGy) were 
considered non-myeloablative. Myeloablative conditioning 
is the regimen with highest intensity and non-myelo-
ablative is the one with lowest intensity, whereas the 
reduced-intensity regimens fall into an intermediate 
intensity category that does not fit the definition of 
myeloablative or non-myeloablative conditioning.
The main outcome measure was event-free survival 
(defined as time from transplantation to death or graft 
failure) assessed throughout the entire follow-up period. 
Graft failure was defined as: failure to achieve an absolute 
neutrophil recovery (ANC) of 0·5 × 10⁹ cells per L or more 
for 3 consecutive days; a decline in ANC to less than 
0·5 × 10⁹ cells per L without recovery, after having 
achieved an ANC 0·5 × 10⁹ cells per L or more; myeloid 
donor chimerism (<5%); or second transplant.15 Our 
definition of graft failure considered donor chimerism 
information collected up to 2 years after transplantation. 
Thereafter, our standardised data-collection forms asked 
whether the patient experienced graft failure (<5% 
donors) and the date of failure.
Other outcomes studied were overall survival (death from 
any cause was considered an event) assessed throughout 
the entire follow-up period, and acute and chronic GVHD 
graded using standard criteria (modified Glucksberg 
grading for acute GVHD and National Institute of Health 
criteria for chronic GVHD).16,17 GVHD is an immuno-
logically mediated complication of transplantation affecting 
multiple organs. Acute GVHD occurs primarily within the 
first 3 months after transplantation and chronic GVHD 
ensues thereafter. Occurrence of acute GVHD of grade 2–4 
and any chronic GVHD were considered events. 
Statistical analysis
The characteristics of patients grouped by donor type 
were compared using the χ² test for categorical variables. 
The proportion of patients with graft failure and acute 
and chronic GVHD were calculated using the cumu lative 
incidence estimator to accommodate competing risks (ie, 
death).18 Risk factors associated with event-free survival, 
overall survival, graft failure, and acute and chronic 
GVHD were examined using the Cox proportional 
hazards model;19 hazard ratios (HRs) and their associated 
95% CIs were estimated for all outcomes. The 
probabilities of event-free survival and overall survival 
were generated from final Cox regression models.20 
Surviving patients were censored at last follow-up.
Variables considered were age, sex, performance score, 
comorbidity index, recipient cytomegalovirus serostatus, 
donor type, conditioning regimen intensity, graft type, 
and transplantation period (2008–12 vs 2013–17, chosen 
arbitrarily). Age was treated as a binary variable (≤12 years 
vs 13–49 years). The age cutoff at 13 years was determined 
statistically using the minimum p-value approach. To 
determine the optimal age cutoff, we used a series of two-
sample tests for multiple possible candidate dichoto-
misations of age. For each candidate cutoff, an 
appropriate Cox model with a single binary covariate for 
age was constructed and the p value for the Wald test was 
obtained. The optimal age cutoff was defined as that 
candidate cutoff with the smallest p value. All variables 
met the assumption of proportional hazards and there 
were no first-order interactions between the variables 
held in Cox models.
The level of significance set for the study was p less 
than 0·05. All p values are two-sided and all analyses 
were done using SAS version 9.4.
Role of the funding source
The funder of the study played no role in study design, 
data collection, data analysis, data interpretation, or 
Figure 1: Study profile
1417 patients included in CIBMTR database 
421 excluded
328 received transplants before 2008
7 aged ≥50 years
86 did not consent
996 patients with sickle cell disease assessed for eligibility
910 included in this analysis
137 haploidentical transplantation
558 HLA-matched sibling transplantation
111 HLA-matched unrelated donor transplantation
104 mismatched unrelated donor transplantation
86 excluded
43 audit failed
10 received uncommon conditioning 
regimens
13 did not receive prophylaxis for 
graft-versus-host disease 
20 were inadequately followed up
Downloaded for Anonymous User (n/a) at UCSF Benioff Children's Hospital Oakland from ClinicalKey.com by Elsevier on October 01, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
Articles
4 www.thelancet.com/haematology   Published online September 5, 2019   http://dx.doi.org/10.1016/S2352-3026(19)30154-1
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Of 1417 patients with sickle cell disease who had a 
transplantation reported to the CIBMTR, 996 (70%) 
underwent transplantation during the period of interest, 
of whom 910 (91%) were eligible for this study (figure 1). 
We excluded 43 (4%) of 996 patients from two transplant 
centres that failed data accuracy audit: 10 patients received 
uncommon conditioning regimens (ie, regimens 
containing treosulfan [n=8] and TBI dose ≥1000 cGy 
[n=2]), 13 did not receive prophylaxis for GVHD, and 20 
(2%) were inadequately followed up after transplantation. 
Treosulfan can only be used as an investigational new 
drug in the USA and high-dose TBI (≥1000 cGy) regimens 
are rarely used for sickle cell disease. 185 (20%) of these 
910 patients were included in earlier reports7,8,10–13 
(111 [12%] received a transplant from HLA-matched 
siblings, 39 [4%] from haploidentical relatives, 28 [3%] 
from HLA-matched unrelated donors, and seven [1%] 
from HLA-mismatched unrelated donors).
There were no differences in sex distribution or recipient 
cytomegalovirus serostatus between the groups. However, 
recipients of transplants from HLA-matched siblings and 
from HLA-matched and HLA-mismatched unrelated 
donors were younger and more likely to have performance 
scores of 90 or 100 and a HCT-comorbidity index of 0–2 
than recipients of transplants from haploidentical related 
HLA-matched 
sibling, 
n=558
Haploidentical 
relative, 
n=137
HLA-matched 
unrelated donor, 
n=111
HLA-mismatched 
unrelated donor, 
n=104
Genotype
Hb SS (sickle cell disease) 534 (96%) 132 (96%) 106 (95%) 95 (91%)
Hb Sβ (sickle β-thalassemia) 24 (4%) 5 (4%) 5 (5%) 9 (9%)
Age at transplant, years
Median 11 (6–17) 19 (13–27) 14 (9–17) 10 (6–16)
≤10 295 (53%) 22 (16%) 35 (32%) 56 (54%) 
11–17 139 (25%) 38 (28%) 54 (49%) 34 (33%)
18–29 82 (15%) 50 (36%) 17 (15%) 12 (12%)
30–49 42 (8%) 27 (20%) 5 (5%) 2 (2%)
Sex
Male 311 (56%) 74 (54%) 53 (48%) 51 (49%)
Female 247 (44%) 63 (46%) 58 (52%) 53 (51%)
Cytomegalovirus serostatus
Positive 288 (52%) 64 (47%) 54 (49%) 49 (47%)
Negative 269 (48%) 72 (53%) 57 (51%) 55 (53%)
Not reported 1 (<1%) 1 (<1%) ·· ··
Performance status
≤80 80 (14%) 42 (31%) 18 (16%) 20 (19%)
90–100 472 (85%) 90 (66%) 90 (81%) 80 (77%)
Not reported 6 (1%) 5 (4%) 3 (3%) 4 (4%)
HCT-comorbidity index
0–2 404 (72%) 76 (55%) 79 (71%) 79 (76%)
≥3 154 (28%) 61 (45%) 32 (29%) 25 (24%)
Graft type
Bone marrow 437 (78%) 63 (46%) 99 (89%) 32 (31%)
Peripheral blood 78 (14%) 74 (54%) 12 (11%) 13 (13%)
Umbilical cord blood 43 (8%) ·· ·· 59 (57%)
HLA-match score
8/8 558 (100%) ·· 111 (100%) ··
7/8 ·· ·· ·· 55 (53%)
≤6/8 ·· 137 (100%) ·· 49 (46%)
(Table 1 continues on next page)
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HLA-matched 
sibling, 
n=558
Haploidentical 
relative, 
n=137
HLA-matched 
unrelated donor, 
n=111
HLA-mismatched 
unrelated donor, 
n=104
(Continued from previous page)
Conditioning regimen
Myeloablative 348 (62%) 34 (25%) 49 (44%) 47 (45%)
Busulfan plus cyclophosphamide 250 (45%) 21 (15%) 14 (13%) 27 (26%)
Busulfan plus fludarabine 85 (15%) 6 (4%) 26 (23%) 17 (16%)
Busulfan plus fludarabine and thiotepa 2 (<1%) 7 (5%) 2 (2%) 2 (2%)
Melphalan plus fludarabine 11 (2%) 7 (6%) 1 (<1%)
Reduced intensity 129 (23%) 14 (10%) 57 (51%) 51 (49%)
Busulfan plus fludarabine 5 (1%) ·· ·· ··
Melphalan plus fludarabine 110 (20%) 1 (<1%) 41 (37%) 24 (23%)
Melphalan plus fludarabine and thiotepa 14 (3%) 13 (9%) 16 (14%) 27 (27%)
Non-myeloablative* 81 (15%) 89 (65%) 5 (5%) 6 (6%)
TBI plus cyclophosphamide 14 (3%) 6 (4%) ·· ··
TBI plus cyclophosphamide and fludarabine 9 (2%) 55 (40%) 3 (3%) 3 (3%)
TBI plus cyclophosphamide, fludarabine, and thiotepa 1 (<1%) 9 (7%) ·· ··
TBI plus melphalan 2 (<1%) ·· 1 (1%) 2 (2%)
TBI plus fludarabine ·· 4 (3%) 1 (1%) ··
TBI alone 55 (10%) 15 (11%) ·· 1 (<1%)
In-vivo T-cell depletion
Anti-thymocyte globulin 249 (45%) 95 (69%) 29 (26%) 25 (24%)
Alemtuzumab 289 (52%) 30 (22%) 75 (68%) 66 (63%)
None 20 (4%) 12 (9%) 7 (6%) 13 (13%)
Graft-versus-host disease prophylaxis
Ex-vivo T-cell depletion ·· 10 (7%) 1 (1%) ··
CD34 cell selection 2 (<1%) 22 (16%) 4 (4%) 12 (12%)
Post-HCT cyclophosphamide plus sirolimus and 
mycophenolate
3 (1%) 47 (34%) 1 (<1%) 1 (1%)
Post-HCT cyclophosphamide plus sirolimus ·· 21 (15%) ·· ··
Post-HCT cyclophosphamide plus calcineurin inhibitor 
and mycophenolate
4 (1%) 14 (10%) 1 (<1%) ··
Calcineurin inhibitor plus mycophenolate 129 (23%) 10 (7%) 27 (24%) 57 (55%)
calcineurin inhibitor plus methotrexate 324 (58%) 4 (3%) 65 (59%) 26 (25%)
Calcineurin inhibitor plus sirolimus 2 (<1%) ·· 2 (2%) 1 (1%)
Calcineurin inhibitor alone 26 (5%) 9 (7%) 10 (9%) 7 (7%)
Sirolimus alone 68 (12%) ·· ·· ··
Transplantation period
2008–12 211 (38%) 33 (24%) 38 (34%) 45 (43%)
2013–17 347 (62%) 104 (76%) 73 (66%) 59 (57%)
Data are n (%) and median (IQR). HLA=human leukocyte antigen. HCT=haematopoietic cell transplantation. TBI=total body irradiation. *TBI dose for HCTs from 
HLA-matched siblings was 300 cGy for the TBI alone and TBI plus cyclophosphamide regimens and 200 cGy for all other TBI-containing regimens (except for two patients 
who received TBI 300 cGy with the TBI plus cyclophosphamide and fludarabine regimen); TBI dose for HCTs from haploidentical related donors was 400 cGy for TBI alone 
regimen (except for one patient who received a TBI dose of 300 cGy), 400 cGy for the TBI plus cyclophosphamide regimen, 200 cGy for most patients receiving the TBI plus 
cyclophosphamide and fludarabine regimen (except for six patients who received TBI 300 cGy and 14 patients who received TBI 400 cGy), and 200 cGy for the TBI plus 
cyclophosphamide, fludarabine, and thiotepa regimen and the TBI plus cyclophosphamide regimen; TBI dose for HCTs from matched unrelated donors was 300 cGy for the 
TBI plus cyclophosphamide and fludarabine regimen and the TBI plus cyclophosphamide regimen and 200 cGy for the TBI plus melphalan regimen; TBI dose for HCTs from 
mismatched unrelated donors was 400 cGy for the TBI alone regimen, 300 cGy for the TBI plus cyclophosphamide and fludarabine regimen, and 200 cGy for one patient and 
400 cGy for the other patient who received the TBI plus melphalan regimen.
Table 1: Baseline characteristics
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donors. HLA-matched siblings were the predominant 
donor group and bone marrow was the predominant graft 
for HLA-matched sibling and HLA-matched unrelated 
donor transplants. The predom inant graft source was 
peripheral blood for transplants from haploidentical 
related donors and umbilical cord blood for transplants 
from HLA-mismatched unrelated donors. The pre-
dominant conditioning regimen was myeloablative for 
recipients of transplants from HLA-matched sibling 
donors and non-myeloablative for recipients of transplants 
from haploidentical related donors. Myeloablative and 
reduced-intensity regimens were equally likely to be used 
for recipients of transplants from HLA-matched and HLA-
mismatched unrelated donors. Transplantations were 
more common in the period 2013–17 than in 2008–12, 
especially those from haploidentical related donors. The 
median follow-up of surviving patients after trans plan-
tation was 36 months (IQR 18–60) for recipients of 
transplants from HLA-matched siblings, 25 months 
(12–48) for recipients of transplants from haploidentical 
related donors, 37 months (23–60) for recipients of 
transplants from HLA-matched unrelated donors, and 
47 months (24–72) for recipients of transplants from HLA-
mismatched unrelated donors (table 1).
Event-free survival was decreased in patients aged 13 
years or older versus those aged 12 years or younger 
(HR 1·74, 1·24–2·45), in those who received reduced-
intensity conditioning regimens versus non-myeloablative 
regimens (1·97, 1·15–3·36), and after transplantation of 
grafts from donors who were not HLA-matched siblings 
versus HLA-matched siblings (5·30, 3·17–8·86, for 
haploidentical related donors; 3·71, 2·39–5·75, for HLA-
matched unrelated donors; and 4·34, 2·58–7·32, for HLA-
mismatched unrelated donors; table 2 and figure 2A). 
Event-free survival did not differ between myeloablative 
and reduced-intensity regimens (0·80, 0·56–1·13; 
p=0·21), between HLA-matched unrelated donors and 
haploidentical related (1·43, 0·81–2·50; p=0·21) or 
mismatched unrelated (1·17, 0·67–2·05; p=0·58) donors, 
or between mismatched unrelated and haploidentical 
related donors (1·22, 0·65–2·27; p=0·98). 3-year event-
free survival is shown in the appendix (p 1).
Donor type was associated with graft failure. Compared 
with recipients of transplants from HLA-matched sibling 
the proportion of patients with graft failure increased 
among recipients of transplants from haploidentical 
relatives (HR 6·58, 95% CI 3·55–12·21) and HLA-
matched (2·88, 1·54 –5·37) and HLA-mismatched (4·38, 
2·31–8·31) unrelated donors (table 2, figure 2B). Graft 
failure occurred in a greater proportion of recipients of 
transplants from haploidentical relatives (2·27, 
1·09–4·76; p=0·028), but not HLA-mismatched unrelated 
donors (1·52, 0·71–3·24; p=0·28), than from HLA-
matched unrelated donors. Graft failure did not differ 
between mismatched unrelated and haploidentical 
related donor transplants (0·67, 0·31–1·44; p=0·30). 
Graft failure occurred less frequently in women than in 
Events/patients Hazard ratio
(95% CI)
p value
Event-free survival
Age, years
≤12 72/491 1 (ref) ··
13–49 102/418 1·74 (1·24–2·45) 0·0014
Regimen intensity 0·046
Non-myeloablative 36/181 1 (ref) ··
Myeloablative 75/478 1·57 (0·95–2·61) 0·079
Reduced intensity 63/250 1·97 (1·15–3·36) 0·013
Donor type ·· ·· <0·0001
HLA-matched sibling 52/557 1 (ref) ··
Haploidentical related 45/137 5·30 (3·17–8·86) <0·0001
HLA-matched unrelated 38/111 3·71 (2·39–5·75) <0·0001
HLA-mismatched unrelated 39/104 4·34 (2·58–7·32) <0·0001
Graft type
Bone marrow 105/630 1 (ref) 0·33
Peripheral blood 40/177 1·01 (0·66–1·54) 0·98
Umbilical cord blood 29/102 1·52 (0·87–2·65) 0·14
HCT comorbidity index
0–2 125/637 1 (ref) ··
≥3 49/272 0·86 (0·61–1·24) 0·42
Performance status
≤80 29/160 1 (ref) ··
90–100 143/731 1·33 (0·87–2·04) 0·19
Recipient cytomegalovirus serology
Negative 81/454 1 (ref) ··
Positive 93/455 1·33 (0·98–1·80) 0·065
Sex
Male 95/488 1 (ref) ··
Female 79/421 0·86 (0·63–1·16) 0·31
Transplantation period
2008–12 73/327 1 (ref) ··
2013–17 101/582 0·98 (0·71–1·36) 0·89
Graft failure
Age, years
≤12 54/491 1 (ref) ··
13–49 59/418 1·17 (0·76–1·82) 0·47
Regimen intensity 0·28
Non-myeloablative 31/181 1 (ref) ··
Myeloablative 44/478 1·04 (0·56–1·91) 0·91
Reduced intensity 38/250 1·46 (0·77–2·79) 0·25
Donor type ·· ·· <0·0001
HLA-matched sibling 32/557 1 (ref) ··
Haploidentical related 36/137 6·58 (3·55–12·21) <0·0001
HLA-matched unrelated 16/111 2·88 (1·54–5·37) 0·00090
HLA-mismatched unrelated 29/104 4·38 (2·31–8·31) <0·0001
(Table 2 continues on next page)
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men (0·61, 0·42 – 0·90; table 2). The proportion of 
patients with graft failure at 3 years is shown in the 
appendix (p 1).
Overall survival was lower in patients aged 13 years or 
older than in those younger than 13 years (HR 3·15, 
95% CI 1·86–5·34), in those who received myeloablative 
(4·62, 1·87–11·44) and reduced-intensity (3·79, 
1·46–9·84) conditioning than in those who received 
nonmyeloablative regimens, and after transplantation of 
grafts from donors who were not HLA-matched siblings 
than HLA-matched siblings (2·94, 1·26–6·87, for 
haploidentical related donors; 5·12, 2·79–9·40, for HLA-
matched unrelated donors; and 4·88, 2·22–10·75, for 
HLA-mismatched unrelated donors; table 2, figure 2C). 
Overall survival did not differ between myeloablative and 
reduced intensity regimens (1·22, 0·74–2·02; p=0·44). 
Compared with recipients of transplants from HLA-
matched unrelated donors,  overall survival did not differ 
in recipients of transplants from haploidentical related 
donors (0·57, 0·24–1·35; p=0·20) or from mismatched 
unrelated donors (0·95, 0·44–2·05; p=0·90). Similarly, 
overall survival did not differ between mismatched 
unrelated donors and haploidentical related donors 
(0·60, 0·24–1·49; p=0·27). 3-year overall survival is shown 
in the appendix (p 1).
The proportion of patients with acute GVHD was 
increased with myeloablative (HR 4·14, 95% CI 
1·68–10·22) and reduced-intensity (4·43, 1·73–11·35) 
conditioning versus non-myeloablative regimens; after 
transplantation of grafts from haploidentical related 
donors (2·27, 1·08–4·77), HLA-matched unrelated 
donors (3·84, 2·22–6·63), and HLA-mismatched 
unrelated donors (6·14, 3·66–10·28) versus HLA-
matched siblings, and in the transplantation period 
2013–17 (1·74, 1·06–2·84) versus 2008–12 (table 3). The 
proportion of patients with acute GVHD at 100 days is 
shown in the appendix p 1.
Acute GVHD risks did not differ between myeloablative 
and reduced-intensity conditioning regimens (0·93, 
0·60–1·46; p=0·77). The risk of acute GVHD did not 
differ between transplants from HLA-matched unrelated 
donors and recipients of transplants from haploidentical 
related donors (0·63, 0·27–1·47; p=0·29) or mismatched 
unrelated donors (1·27, 0·62–2·59, p=0·51), or between 
recipients of transplants from HLA-mismatched 
unrelated donors and from haploidentical related donors 
(0·37, 0·20–1·20; p=0·12). The severity of acute GVHD 
did not differ by donor type (p=0·35; data not shown).
The proportion of patients with chronic GVHD was 
increased in patients aged 13 years or older versus those 
younger than 13 years (HR 1·46, 95% CI 1·06–2·00), 
those treated with myeloablative (2·82, 1·51–5·27) and 
reduced-intensity (4·00, 2·11–7·55) conditioning versus 
non-myeloablative regimens, and those who received a 
transplant from an HLA-matched unrelated donor (1·70, 
1·14–2·54) versus an HLA-matched sibling (table 3). The 
proportion of patients with chronic GVHD also increased 
Events/patients Hazard ratio
(95% CI)
p value
(Continued from previous page)
Graft type
Bone marrow 60/630 1 (ref) 0·09
Peripheral blood 28/177 1·02 (0·61–1·70) 0·95
Umbilical cord blood 25/102 2·07 (1·08–3·96) 0·028
HCT comorbidity index
0–2 81/637 1 (ref) ··
≥3 32/272 0·77 (0·49–1·21) 0·26
Performance status
≤80 23/160 1 (ref) ··
90–100 88/731 1·03 (0·62 –1·70) 0·92
Recipient cytomegalovirus serology
Negative 53/454 1 (ref) ··
Positive 60/455 1·32 (0·90–1·92) 0·16
Sex
Male 71/488 1 (ref) ··
Female 42/421 0·61 (0·42–0·90) 0·013
Transplantation period
2008–12 47/327 1 (ref) ··
2013–17 66/582 1·01 (0·67–1·51) 0·96
Overall survival
Age, years
≤12 22/491 1 (ref) ··
13–49 54/418 3·15 (1·86–5·34) <0·0001
Regimen intensity ·· ·· 0·004
Non-myeloablative 7/181 1 (ref)
Myeloablative 41/478 4·62 (1·87–11·44) 0·00093
Reduced intensity 28/250 3·79 (1·46–9·84) 0·0062
Donor type ·· ·· <0·0001
HLA-matched sibling 21/557 1 (ref)
Haploidentical related 13/137 2·94 (1·26–6·87) 0·013
HLA-matched unrelated 26/111 5·12 (2·79–9·40) <0·0001
HLA-mismatched unrelated 16/104 4·88 (2·22–10·75) <0·0001
Graft type
Bone marrow 50/630 1 (ref) 0·09
Peripheral blood 19/177 1·02 (0·61–1·70) 0·95
Umbilical cord blood 7/102 0·58 (0·22–1·55) 0·27
HCT comorbidity index
0–2 53/637 1 (ref) ··
≥3 23/272 1·15 (0·68–1·93) 0·60
Performance status
≤80 10/160 1 (ref) ··
90–100 65/731 1·71 (0·85–3·45) 0·13
Recipient cytomegalovirus serology
Negative 34/454 1 (ref) ··
Positive 42/455 1·35 (0·85–2·14) 0·20
(Table 2 continues on next page)
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after reduced intensity compared with myeloablative 
conditioning regimens (1·41, 1·03–1·96; p=0·031). The 
risk of chronic GVHD did not differ between recipients 
of transplants from HLA-matched unrelated donors and 
haploidentical related donors (1·03, 0·54–1·96, p=0·93) 
or HLA-mismatched unrelated donors (0·93, 0·52–1·67, 
p=0·82), or between recipients of transplants from HLA-
mismatched unrelated and from haploidentical related 
donors (1·09, 0·54–2·22, p=0·79). The severity of chronic 
GVHD did not differ by donor type (p=0·12; data not 
shown). The proportion of patients with chronic GVHD at 
3 years is shown in the appendix p 1.
A subset analysis of 558 recipients of transplants from 
HLA-matched sibling was done to assess the effect of 
conditioning regimen intensity. Conditioning regimen 
intensity was not associated with overall sur vival. However, 
prevalence of graft failure increased after reduced-
intensity conditioning compared with myelo ablative (HR 
0·28, 95% CI 0·13–0·57; p<0·0001) and non-myeloablative 
(0·29, 0·08–1·00; p=0·049) regimens. Consequently, 
event-free survival was decreased after reduced-intensity 
conditioning com pared with myeloablative (0·38, 
0·21–0·67; p=0·00080) and non-myeloablative (0·36, 
0·13–0·94; p=0·036) regimens. Consistent with the main 
analysis, the HR for overall survival was three-times 
higher in patients aged 13 years or older (3·25, 1·27–8·29, 
p=0·014) than in those younger than 13 years.
Six (1%) of 910 patients developed malignant neoplasm 
(acute myeloid leukemia [n=2], myelodysplastic 
syndrome [n=2], hepatic myelofibroblastic tumor [n=1], 
and TCR-β gene rearrangement positive T-cell large 
granular lymphocytic leukemia [n=1]; appendix p 2). 
Three of six patients with malignant neoplasm died. The 
point estimate for the risk of developing a post-trans-
plantation malignancy was seven times higher with non-
myeloablative than with reduced-intensity regimens, 
although it was not significant (HR 7·08, 95% CI 
0·82–60·63; p=0·07). None of the six patients had 
chronic GVHD. There were no cases of post-trans-
plantation malignant neoplasm with myeloablative 
regimens. Nine patients developed Epstein-Barr 
Events/patients Hazard ratio
(95% CI)
p value
(Continued from previous page)
Sex
Male 31/488 1 (ref) ··
Female 45/421 1·49 (0·94–2·38) 0·09
Transplantation period
2008–12 31/327 1 (ref) ··
2013–17 45/582 0·94 (0·57–1·56) 0·81
Data are n/N, unless otherwise indicated. Overall p values for multiple comparison are reported when more 
than two exposure categories are tested. HCT=haematopoietic cell transplantation. ref=reference.
Table 2: Risk factors for event-free survival, graft failure, and overall survival
Figure 2: Event free survival (A), graft failure (B), and overall survival (C) 
by donor type
Data are number at risk (numbers censored). HLA=human leukocyte antigen. 
HR=hazard ratio.
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virus-positive lymphoproliferative disease at a median of 
5 months (IQR 3–12) after transplantation with all having 
had in-vivo T-cell depletion with anti-thymocyte globulin 
or alemtuzumab. Notably, one (<1%) of 421 patients for 
whom pre-transplantation and post-transplantation 
sickle cell disease-specific data were available reported 
acute chest syndrome and six (1%) patients had a stroke; 
all seven patients had full donor myeloid chimerism.
Discussion
There were two key findings in this retrospective analysis 
that warrant caution when considering alternative donor 
transplantation as a potentially curative option for 
patients with sickle cell disease. Mortality and prevalence 
of graft failure were increased after any alternative donor 
transplantation compared with HLA-matched sibling 
transplantation, which resulted in substantially decreased 
event-free survival. To our knowledge, this is the first 
study to assess allogeneic transplantation outcomes 
for patients with sickle cell disease who received 
transplantations from HLA-matched sibling donors or 
transplantations from alternative donors (haploidentical 
related donors, HLA-matched unrelated donors, and 
HLA-mismatched unrelated donors). The study also 
addressed the effect of conditioning regimen intensity on 
transplant outcomes. Myeloablative and reduced-intensity 
regimens were associated with increased mortality as well 
as acute and chronic GVHD. Conditioning regimen 
intensity was not associated with graft failure.
Increased mortality and prevalence of graft failure after 
transplantation from HLA-mismatched unrelated donors 
has been reported for non-malignant diseases but those 
studies21,22 did not include many patients who received 
transplants for haemoglobinopathies. Our findings 
confirm the adverse effect of HLA disparity on survival 
outcomes and graft failure after transplantation in 
patients with sickle cell disease. The timing of graft 
failure differed by donor type in patients with sickle cell 
disease. Graft failure after transplantation from HLA-
matched siblings and unrelated donors primarily 
occurred within 1–2 years after transplantation. By con-
trast, graft failure was more common 2–3 years after 
haploidentical related donor transplantation. This is 
particularly relevant in light of the improved outcomes 
reported in two recent phase 2 trials23,24 of transplantations 
from haploidentical related donor with 15 and 12 patients 
with sickle cell disease. Both trials used the post-
transplantation cyclophosphamide approach to overcome 
the HLA barrier. One trial23 reported donor engraftment 
in 14 (93%) of 15 patients at 6 months23 and the other 
trial24 reported full or mixed donor engraftment 11 (92%) 
of 12 patients in the first year after transplantation. 
Longer follow-up of these patients is needed to confirm 
sustained donor engraftment. We did not find an 
association between graft failure and conditioning 
regimen tested (myeloablative, reduced intensity, and 
non-myeloablative).
Events/patients Hazard Ratio
(95% confidence 
interval)
p value
Grade 2-4 acute graft-versus-host disease
Age, years
≤12 46/446 1 (ref) ··
13–49 49/377 1·39 (0·89–2·18) 0·14
Regimen intensity ·· ·· 0·0062
Non-myeloablative 7/171 1 (ref)
Myeloablative 51/440 4·14 (1·68–10·22) 0·0020
Reduced intensity 37/212 4·43 (1·73–11·35) 0·0019
Donor type ·· ·· <0·0001
HLA-matched sibling 32/513 1 (ref) ··
Haploidentical related 11/126 2·27 (1·08–4·77) 0·03
HLA-matched unrelated 23/97 3·84 (2·22–6·63) <0·0001
HLA-mismatched unrelated 29/87 6·14 (3·66–10·28) <0·0001
Graft type
Bone marrow 58/565 1 (ref) 0·37
Peripheral blood 15/163 0·98 (0·50–1·91) 0·95
Umbilical cord blood 22/95 1·61 (0·81–3·20) 0·18
HCT comorbidity index
0–2 65/564 1 (ref) ··
≥3 30/259 0·94 (0·59–1·49) 0·79
Performance status
≤80 22/149 1 (ref) ··
90–100 72/658 0·71 (0·42–1·19) 0·19
Recipient cytomegalovirus serology
Negative 45/411 1 (ref)
Positive 50/412 1·19 (0·79–1·80) 0·39
Sex
Male 45/439 1 (ref)
Female 50/384 1·16 (0·77–1·76) 0·47
Transplantation period
2008–12 24/285 1 (ref)
2013–17 71/538 1·74 (1·06–2·84) 0·028
Chronic graft-versus-host disease
Age, years
≤12 98/491 1 (ref)
13–49 92/419 1·46 (1·06–2·00) 0·019
Regimen intensity <0·0001
Non-myeloablative 17/181 1 (ref)
Myeloablative 97/478 2·82 (1·51–5·27) 0·0012
Reduced intensity 76/250 4·00 (2·11–7·55) <0·0001
Donor type 0·017
HLA-matched sibling 101/557 1 (ref)
Haploidentical related 22/137 1·75 (0·55–3·11) 0·055
HLA-matched unrelated 37/111 1·70 (1·14–2·54) 0·0087
HLA-mismatched unrelated 30/104 1·59 (0·95–2·67) 0·08
(Table 3 continues on next page)
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The concept of less intense conditioning regimens 
(reduced intensity or non-myeloablative) was introduced 
to overcome mortality risks associated with myeloablation 
in less fit patients or for diseases for which myeloablation 
was not desirable. Therefore, the finding that mortality 
risks were four times higher with both myeloablative and 
reduced-intensity regimens than with non-myeloablative 
regimens was unexpected. The recorded increased 
mortality might be explained in part by the increased 
risks of acute and chronic GVHD with myeloablative and 
reduced intensity regimens. These regimens relied 
on standard GVHD prophylaxis, which included a 
calcineurin inhibitor alone or with methotrexate, myco-
phenolate, or sirolimus. The non-myeloablative regimens 
used a different strategy. In the setting of HLA-matched 
sibling transplantation, the low-dose TBI approach incor-
porates an attempt at tolerance induction through the 
use of lymphocyte reduction with alemtuzumab plus 
mTOR inhibition with sirolimus during recovery.25 This 
tolerance is blocked in vitro and in animal models with 
calcineurin inhibitor.25 Similarly, for transplantation 
from haploidentical related donors, post-transplantation 
treatment with cyclophosphamide induces early immune 
tolerance mediated by the destruction of alloreactive 
donor and recipient T cells, and any remaining 
alloreactivity is counterbalanced by increasing the 
number T regulatory cells.26 A delayed but long-lasting 
intrathymic clonal deletion of anti-host T cells maintains 
long-term immune tolerance.26 Tolerance induction and 
low prevalence of GVHD associated with low-intensity 
regimens are likely to have contributed to the high event-
free survival and overall survival in these patients. 
Increased prevalence of acute GVHD after the 
2008–12 period can be explained by the increasing 
numbers of transplantation from unrelated donors.27 On 
the basis of these observations, we hypothesise that 
immune tolerance induction, rather than regimen 
intensity per se, is the key driver of survival after trans-
plantation for treatment of sickle cell disease.
Age at transplantation was an important predictor of 
survival in this study. The risk of death is three times 
higher in a patient aged 13 years or older than in a younger 
patient, assuming the type of donor and conditioning 
regimen intensity are the same for both patients. Although 
almost half the study population was aged 13 years or 
older, we did not find another age cutoff associated with 
survival differences. Only seven trans plantations were 
reported in patients aged 50 years or older and they were 
not included in the current analyses. The effect of age in 
adults can only be studied properly in a larger adult 
population than represented in our population, and this is 
a limitation of our study. The timing of transplantation is 
dependent on physician and patient choice, donor 
availability, and access to health care. With the exception 
of stroke, severity of symptoms of sickle cell disease that 
prompts referral for transplantation is variable. In the 
absence of a comparative study of transplant recipients 
and those receiving non-transplantation therapies with 
comparable disease severity, we cannot comment on 
whether transplantation from HLA-matched sibling 
should be offered in the first decade of life. With 3-year 
prevalence of chronic GVHD of 18% (95% CI 15–22) after 
transplantation from HLA-matched siblings we cannot 
recommend transplantation for asymptomatic children or 
for children without severe disease. Consistently with a 
published study,28 we did not record an association 
between comorbidity index and survival.
There are several limitations to our study because of its 
retrospective nature, which include the fact that the 
decision to offer transplantation and its timing, choice of 
conditioning regimen intensity, and choice of alternative 
donor in the absence of a matched sibling were made by 
the treating physicians at each participating institution. 
We acknowledge transplantation strategies are best 
studied in the setting of multicentre trials. Yet, prospective 
studies are challenging as accrual can extend over 5 years 
for funded multicentre transplantation trials.5,11 We did 
not consistently collect information on haemoglobin 
S concentration after transplantation. Our definition of 
graft failure considered donor chimerism collected up to 
2 years after transplantation. Thereafter, our standardised 
data-collection forms asked whether the patient 
experienced graft failure (<5% donors) and the date of 
Events/patients Hazard Ratio
(95% confidence 
interval)
p value
(continued from previous page)
Graft type
Bone marrow 146/630 1 (ref) 0·09
Peripheral blood 20/177 0·55 (0·32–0·94) 0·028
Umbilical cord blood 24/102 0·84 (0·49–1·46) 0·54
HCT comorbidity index
0–2 135/637 1 (ref)
≥3 55/272 1·13 (0·81–1·57) 0·47
Performance status
≤80 34/160 1 (ref)
90–100 152/731 0·86 (0·57–1·28) 0·44
Recipient cytomegalovirus serology
Negative 93/454 1 (ref)
Positive 97/455 1·05 (0·79–1·40) 0·74
Sex
Male 89/488 1 (ref)
Female 101/421 1·32 (0·99–1·77) 0·06
Transplantation period
2008–12 76/327 1 (ref)
2013–17 114/583 1·07 (0·79–1·46) 0·65
HCT=haematopoietic cell transplantation. ref=reference value.
Table 3: Risk factors for acute and chronic graft-versus-host disease
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failure. We did not have data on red blood cell chimerism. 
The occurrence of events such as acute chest syndrome 
and stroke in the setting of full donor chimerism deserves 
further study and such research is best achieved through 
careful longitudinal follow-up focusing on sickle cell 
disease-related complications. We did not collect detailed 
data on sickle cell disease-related complications after 
transplantation to study the occurrence of stroke in 
patients with full myeloid donor chimerism.
Similarly, because of limited follow-up, the recorded 
increased risk of post-transplantation myeloid malig-
nancy after non-myeloablative regimens should be 
further investigated. Whether this finding is a result of 
age, transplantation per se, regimen intensity, or some 
other unknown or unmeasured factor cannot be 
addressed in this study. A 2017 study29 found that the 
standardised incidence ratio for haematologic cancer in 
an unselected population with sickle cell disease is 1·72 
(95% CI 1·17–2·44) and that patients were diagnosed with 
their first primary cancer at a median age of 46 years. 
With increasing numbers of transplantations in young 
adults, in a few years it might be possible to design 
comparative studies on cancer prevalence amongst 
patients with sickle cell disease who received or did not 
receive transplantation. Although our data does not 
favour one alternative donor over another, a decrease by 
20 percentage points in 3-year event-free survival between 
recipients of transplants from haploidentical relatives and 
HLA-matched unrelated donors cannot be ignored. To 
detect a significant difference with 80% power, 
271 patients are needed but our analyses only included 
248 patients.
Allogeneic transplantation is potentially curative, but 
we do not know whether appropriate follow-up might 
reduce the mortality caused by the transplantation 
procedure to less than the mortality caused by 
complications of sickle cell disease. A phase 2 trial 
(NCT02766465) of young adults with severe sickle cell 
disease in the USA addresses this question by assigning 
eligible participants (eligibility criteria are based on 
disease severity and organ function) to either a donor 
group (if they have a suitably matched sibling or 
unrelated donor) or a no-donor group (if they do not have 
a suitable donor). Participants in the donor group are 
expected to undergo transplantation and those in the no-
donor group are expected to receive best available 
standard of care. We acknowledge monetary coverage for 
access to health care is critical to improve survival. Access 
to transplantation for young adults with sickle cell 
disease is also challenging in the USA. The introduction 
of the Coverage with Evidence Determination programme 
by the Center for Medicare and Medicaid Services is 
likely to broaden access to allogeneic transplantation. 
Another potentially curative treatment for sickle cell 
disease that is being pursued is the use of a lentiviral 
vector to add an anti-sickling β-globin gene variant into 
autologous haematopoietic cells.30 This approach is being 
studied in small numbers of patients and definitive 
conclusions will require confirmation of success in larger 
numbers of patients as well as longer follow-up.
In conclusion, our data suggest that event-free survival 
is improved in patients with sickle cell disease who 
receive an allogenic transplantation at age 12 years or 
younger and those with an HLA-matched sibling donor. 
For patients without a matched sibling donor available, 
our data do not favour one alternative donor type over 
another in this setting. Transplantation from alternative 
donors broadens access to this treatment. However, 
strategies aimed at lowering graft failure and GVHD are 
needed before transplantation from these donors can be 
as effective as that from HLA-matched siblings.
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